Company: SHPH
Filing Date: 2025-03-13
Form Type: 424B3
Source: 0001493152-25-010109
Chunk: 63

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-13
Form: 424B3
Chunk 63
---
 cover page of this prospectus and to dealers at a price less a concession not in excess of $0.288 per share of common stock,
or Pre-Funded Warrant in lieu thereof. After the shares of common stock and Pre-Funded Warrants are released for sale to the public,
the Underwriter may change the offering price, the concession, and other selling terms at various times.

Discounts and Commissions

The following table provides information regarding
the amount of the discounts and commissions to be paid to the Underwriter by us, before expenses.

|                                             |     | Per Share |      |     | Per Pre-Funded Warrant |         |     | Total |           |
|:--------------------------------------------|:----|:----------|-----:|:----|:-----------------------|--------:|:----|:------|----------:|
| Public offering price                       |     | $         | 0.30 |     |                        |   0.299 |     | $     | 5,750,000 |
| Underwriting discounts and commissions (4%) |     | $         | .012 |     |                        |    .012 |     | $     |   230,000 |
| Proceeds, before expenses, to us            |     | $         | .288 |     |                        | 0.28704 |     | $     | 5,502,888 |

The Company has agreed to pay
the Underwriter for: (i) reasonable aggregate expense allowance up to $80,000, and (ii) a non-accountable expense allowance equal to one percent (1%) of the gross proceeds received by us from the sale
of the securities in this offering. Prior to the effective date of this prospectus,
we have paid the Underwriter advances of $45,000, including a $25,000 retainer for its legal counsel and a $20,000 retainer for its anticipated
out-of-pocket costs, each of which shall be deducted against legal fees and transaction expenses, respectively. Such advance payments
will be returned to us to the extent such out-of-pocket expenses are not actually incurred in accordance with FINRA Rule 5110(g)(4)(A).

We estimate that our total expenses of the offering,
excluding the estimated underwriting discounts and commissions the fees of Underwriter’s legal counsel and the non-accountable
expense allowance, will be approximately $167,471.

Right of First Refusal

We have granted the Underwriter a right of first refusal